Table 2.
BZD use categorized as levels of defined daily dose (DDD) in the CRM and in the placebo groups at baseline, and at months 1 and 6
| DDD | Baseline | Month 1 | Month 6 | P | P | P |
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | Month 1 vs. baseline | Month 6 vs. baseline | Month 6 vs. month 1 | |
| CRM group | ||||||
| 0 | 0 (0) | 36 (80) | 14 (32) | <0.001 | <0.001 | <0.001 |
| 0.01–0.20 | 0 (0) | 6 (13) | 16 (36) | |||
| 0.21–0.99 | 24 (52) | 1 (2) | 12 (27) | |||
| 1 | 15 (33) | 2 (4) | 1 (2) | |||
| >1 | 7 (15) | 0 (0) | 1 (2) | |||
| Placebo group | ||||||
| 0 | 0 (0) | 41 (91) | 20 (44) | <0.001 | <0.001 | <0.001 |
| 0.01–0.20 | 0 (0) | 3 (7) | 22 (49) | |||
| 0.21–0.99 | 18 (39) | 1 (2) | 2 (4) | |||
| 1 | 25 (54) | 0 (0) | 1 (2) | |||
| >1 | 3 (7) | 0 (0) | 0 (0) |
Interaction between time and groups: P = 0.052, cumulative logistic regression using GEE estimation. DDD values used: for zopiclone 7.5 mg night–1, for zolpidem 10 mg night–1 and for temazepam 20 mg night–1 in participants aged under 70 years and temazepam 10 mg night–1 in subjects aged ≥70 years.